TABLE 2.
The potential of m6A as a diagnostic and prognostic tool in bladder cancer.
| m6A regulator | Source | Detection method | Biomarker potential | References |
|---|---|---|---|---|
| WTAP | tissues | qRT-PCR, WB and IHC | A biomarker for prognosis | Hou et al. (2021) |
| METTL3 | tissues | IHC | A biomarker for prognosis | Chen et al. (2021b) |
| ALKBH5 | tissues | IHC | A biomarker for prognosis | Chang et al. (2021) |
| m6A | tissues | IHC | A biomarker for prognosis | Tsuchiya et al. (2021) |
| IGF2BP3 | tissues | IHC | A biomarker for prognosis | Dai et al. (2021) |
| FTO | tissues | IHC | A biomarker for prognosis | Nie et al. (2021) |
bladder cancer, BC; WTAP, WT1 associated protein; METTL3, methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit.
METTL14, methyltransferase 14, N6-adenosine-methyltransferase subunit; ALKBH5, alkB homolog 5, RNA demethylase.
IGF2BP3, insulin like growth factor 2 mRNA binding protein 3; FTO, FTO alpha-ketoglutarate dependent dioxygenase.
qRT-PCR, quantitative real-time PCR; WB, Western blot; IHC, Immunohistochemistry.